Statin–Ezetimibe Combination Therapy vs Statin Monotherapy on Cardiovascular Outcomes: A Meta-Analysis

The conventional approach to cholesterol is to push the statin dose as high as tolerated before adding a second drug. This meta-analysis makes the case for the opposite: start the combination early.

Pooling 14 studies and more than 108,000 very high-risk patients, the authors compared statin-plus-ezetimibe against statin alone. The combination lowered LDL by an additional 13 mg/dL and, more importantly, translated that into harder benefits: a 19 percent reduction in all-cause mortality, an 18 percent reduction in major adverse cardiovascular events, and a 17 percent reduction in stroke — with no increase in side effects and even slightly fewer discontinuations.

The clinical argument is about getting to goal sooner. Ezetimibe is inexpensive, generic, and well tolerated; pairing it with a statin from the start, rather than waiting through dose escalations, reaches protective LDL levels faster. The implicit theme is efficiency: the quickest safe path to a low LDL, in the patients who most need it.

We rate the evidence strong. Built largely on randomized trials with a very large combined sample and consistent hard endpoints, it supports upfront combination therapy in high-risk patients, with the usual caveat that pooled analyses blend studies of varying design.